Clinical Trial Update: Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 rollover study of weekly paclitaxel (BMS-181339) in patients with head and neck cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• BMS-181339
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-04-08